Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Mathew

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Oncology (Williston Park, N.Y.)|July 10, 2014
The bifunctional role of steroid hormones: implications for therapy in prostate cancerPaul Mathew
Infectious Disorders Drug Targets|June 20, 2025
The Importance of Early Source Control in Persistent MRSA Bacteremia: A Case ReportJack Demirjian, Paul Mathew
Expert Opinion on Investigational Drugs|April 2, 2013
Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptorAaron Rosenberg, Paul Mathew
The Journal of Urology|July 24, 2007
Taxane refractory prostate cancerPaul Mathew, Robert Dipaola
Current Oncology Reports|February 22, 2011
Optimal management of bone metastases in prostate cancerRaid Aljumaily, Paul Mathew
The American Journal of Hospice & Palliative Care|January 19, 2021
An Ethically Justified Approach That Integrates Advance Directives Discussions With Care of the Patient With CancerRima Patel, Paul Mathew
Oncology (Williston Park, N.Y.)|October 21, 2011
Bladder cancer: imperatives for personalized medicineAshish M Kamat, Paul Mathew
Journal of Pain and Symptom Management|May 21, 2005
Cancer pain management in prisons: a survey of primary care practitioners and inmatesJames T Lin, Paul Mathew
HCA Healthcare Journal of Medicine|July 10, 2023
Low Dose Clenbuterol Toxicity: Case Report and Review of LiteratureKenneth Lan, Adarsh Saheba, Paul Mathew
Molecular Cancer Research : MCR|September 4, 2016
Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL InhibitionWenying Ren, Raghav Joshi, Paul Mathew
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Oncology (Williston Park, N.Y.)|July 10, 2014
The bifunctional role of steroid hormones: implications for therapy in prostate cancerPaul Mathew
Infectious Disorders Drug Targets|June 20, 2025
The Importance of Early Source Control in Persistent MRSA Bacteremia: A Case ReportJack Demirjian, Paul Mathew
Expert Opinion on Investigational Drugs|April 2, 2013
Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptorAaron Rosenberg, Paul Mathew
The Journal of Urology|July 24, 2007
Taxane refractory prostate cancerPaul Mathew, Robert Dipaola
Current Oncology Reports|February 22, 2011
Optimal management of bone metastases in prostate cancerRaid Aljumaily, Paul Mathew
The American Journal of Hospice & Palliative Care|January 19, 2021
An Ethically Justified Approach That Integrates Advance Directives Discussions With Care of the Patient With CancerRima Patel, Paul Mathew
Oncology (Williston Park, N.Y.)|October 21, 2011
Bladder cancer: imperatives for personalized medicineAshish M Kamat, Paul Mathew
Journal of Pain and Symptom Management|May 21, 2005
Cancer pain management in prisons: a survey of primary care practitioners and inmatesJames T Lin, Paul Mathew
HCA Healthcare Journal of Medicine|July 10, 2023
Low Dose Clenbuterol Toxicity: Case Report and Review of LiteratureKenneth Lan, Adarsh Saheba, Paul Mathew
Molecular Cancer Research : MCR|September 4, 2016
Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL InhibitionWenying Ren, Raghav Joshi, Paul Mathew
Pageof 7